Introduction: COVID-19 surveillance in congregate settings is important to mitigating disease, but the health and economic impact of testing remains unclear.

Methods: The authors developed a Markov model to project the cost-utility of COVID-19 testing strategies in homeless shelters from the healthcare payer and societal perspective over 1 year. Model inputs utilized data from residents aged ≥18 years across 23 Seattle shelters from January 1, 2020, to May 31, 2021. No in-shelter surveillance was compared with scenarios of 2 COVID-19 testing strategies implemented monthly: polymerase chain reaction (PCR) testing and rapid antigen testing; scenarios in which only PCR testing was available were also evaluated. The primary health outcome was quality-adjusted life years. Interventions were considered cost-effective if the incremental cost-effectiveness ratio was ≤$150,000 per quality-adjusted life year and dominant if they saved costs and provided health effects.

Results: When assuming the availability of both antigen and PCR tests, most rapid antigen testing strategies were cost-effective, whereas PCR testing was dominated by antigen testing. Compared with no in-shelter surveillance, antigen testing increased mean quality-adjusted life years by 0.0009 (0.03% infections averted) at an incremental cost of $97/resident from the healthcare perspective (incremental cost-effectiveness ratio=$112,352/quality-adjusted life year gained) and $8/resident from the societal perspective (incremental cost-effectiveness ratio=$9,627/quality-adjusted life year gained) at 75% vaccination coverage. PCR testing was not cost-effective when antigen testing was available but was cost-effective compared with no surveillance at low vaccination coverage levels (<30% coverage from the healthcare perspective and ≤48% coverage from the societal perspective). Probabilistic sensitivity analysis showed that antigen testing was cost-effective in 62% and 86% of simulations from the healthcare and societal perspectives, respectively.

Conclusions: Modeled findings show that COVID-19 testing in shelters can be a cost-effective pandemic response. Antigen testing remained cost-effective at high vaccination levels, whereas PCR testing was most effective at low vaccination levels if antigen testing was not available.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11889550PMC
http://dx.doi.org/10.1016/j.focus.2024.100307DOI Listing

Publication Analysis

Top Keywords

antigen testing
20
pcr testing
16
testing
13
testing strategies
12
quality-adjusted life
12
incremental cost-effectiveness
12
life year
12
health economic
8
economic impact
8
covid-19 surveillance
8

Similar Publications

Circulating Markers of Systemic Inflammation, Measured After Completion of Neoadjuvant Therapy, Associate With Response in Locally Advanced Rectal Cancer.

Dis Colon Rectum

March 2025

Academic Unit of Surgery, School of Cancer Sciences, College of Medical, Veterinary & Life Sciences, University of Glasgow, New Lister Building, Glasgow Royal Infirmary, Glasgow, United Kingdom.

Background: The extent of neoadjuvant therapy response, prior to surgery, is an important prognosticator in locally advanced rectal cancer. A spectrum of response exists, with a dearth of reliable measurements. The host response to treatment remains unexplored.

View Article and Find Full Text PDF

Influenza infection represents a serious challenge for virological surveillance and healthcare systems in all countries globally. Despite obvious success in control of influenza through vaccination and antiviral drug development, this infection remains poorly controlled due to antigenic drift and fast selection of drug-resistant viral variants. The design of novel drugs with alternative targets and mechanisms of action is, therefore, an important goal for medical science worldwide.

View Article and Find Full Text PDF

Characterisation of the Novel HLA-A*02:1178 Allele Using Next-Generation Sequencing Methods.

HLA

March 2025

Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China.

The HLA-A*02:1178 allele differs from HLA-A*02:07:01:01 by one nucleotide substitution in codon 326 in exon 7.

View Article and Find Full Text PDF

HLA-DRB5*01:02:05 differs from the HLA-DRB5*01:02:01 by one synonymous nucleotide in codon 14 in exon 2.

View Article and Find Full Text PDF

HLA-C*15:02:01:69Q differs from HLA-C*15:02:01:01 by a single substitution at the genomic nucleotide position 2727 in intron 7.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!